Anti-inflammatory effect of pelubiprofen, 2-[4-(oxocyclohexylidenemethyl)- phenyl]propionic acid, mediated by dual suppression of COX activity and LPS-induced inflammatory gene expression via NF-κB inactivation

Journal of Cellular Biochemistry

Volumn 112, Issue 12, 2011, Pages 3594-3603

  Shin, Ji Sun ^a   Baek, Seung Ryel ^b   Sohn, Se Il ^b   Cho, Young Wuk ^a   Lee, Kyung Tae ^a  

^a Kyung Hee University   (South Korea)

^b Daewoong Pharmaceutical Co Ltd   (South Korea)

Author keywords

Cyclooxygenase; Cytokines; Nitric oxide; Nuclear factor B; Paw EDEMA; Pelubiprofen

Indexed keywords

CARRAGEENAN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; I KAPPA B ALPHA; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PELUBIPROFEN; PROSTAGLANDIN E2; SYNAPTOTAGMIN I; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION; IC 50; IMMUNOMODULATION; LEUKOCYTE MIGRATION; MACROPHAGE; MALE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CYCLOOXYGENASE INHIBITORS; DNA PRIMERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; INHIBITORY CONCENTRATION 50; LIPOPOLYSACCHARIDES; NF-KAPPA B; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

RATTUS;

EID: 80055005126     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23290     Document Type: Article

References (37)

1. Adhikari A, Xu M, Chen ZJ,. 2007. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 26: 3214-3226. (Pubitemid 46763016)
2. Barton GM, Medzhitov R,. 2003. Toll-like receptor signaling pathways. Science 300: 1524-1525. (Pubitemid 36682871)
3. Ben-Neriah Y,. 2002. Regulatory functions of ubiquitination in the immune system. Nat Immunol 3: 20-26. (Pubitemid 34065613)
4. Callejas NA, Fernandez-Martinez A, Castrillo A, Bosca L, Martin-Sanz P,. 2003. Selective inhibitors of cyclooxygenase-2 delay the activation of nuclear factor kappa B and attenuate the expression of inflammatory genes in murine macrophages treated with lipopolysaccharide. Mol Pharmacol 63: 671-677. (Pubitemid 36297339)
5. Chang L, Karin M,. 2001. Mammalian MAP kinase signalling cascades. Nature 410: 37-40. (Pubitemid 32225829)
6. Craig R, Larkin A, Mingo AM, Thuerauf DJ, Andrews C, McDonough PM, Glembotski CC,. 2000. p38 MAPK and NF-kappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system. J Biol Chem 275: 23814-23824. (Pubitemid 30624667)
7. Fratelli M, Minto M, Crespi A, Erba E, Vandenabeele P, Del Soldato P, Ghezzi P,. 2003. Inhibition of nuclear factor-kappaB by a nitro-derivative of flurbiprofen: A possible mechanism for antiinflammatory and antiproliferative effect. Antioxid Redox Signal 5: 229-235. (Pubitemid 36457598)
8. Ghosh S, Karin M,. 2002. Missing pieces in the NF-kappaB puzzle. Cell 109 (Suppl): S81-S96.
9. Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, Koboldt CM, Muhammad JL, Zweifel BS, Masferrer JL, Isakson PC, Seibert K,. 2005. Valdecoxib: Assessment of cyclooxygenase-2 potency and selectivity. J Pharmacol Exp Ther 312: 1206-1212. (Pubitemid 40293782)
10. Grilli M, Pizzi M, Memo M, Spano P,. 1996. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science 274: 1383-1385. (Pubitemid 26391464)
11. Jaksch W, Dejaco C, Schirmer M,. 2008. 4 years after withdrawal of rofecoxib: Where do we stand today? Rheumatol Int 28: 1187-1195.
12. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS,. 1999. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5: 1418-1423.
13. Kang YJ, Kusler B, Otsuka M, Hughes M, Suzuki N, Suzuki S, Yeh WC, Akira S, Han J, Jones PP,. 2007. Calcineurin negatively regulates TLR-mediated activation pathways. J Immunol 179: 4598-4607.
14. Karin M, Ben-Neriah Y,. 2000. Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity. Annu Rev Immunol 18: 621-663. (Pubitemid 30365393)
15. Kim JY, Park SJ, Yun KJ, Cho YW, Park HJ, Lee KT,. 2008. Isoliquiritigenin isolated from the roots of Glycyrrhiza uralensis inhibits LPS-induced iNOS and COX-2 expression via the attenuation of NF-kappaB in RAW 264.7 macrophages. Eur J Pharmacol 584: 175-184.
16. Kopp E, Ghosh S,. 1994. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265: 956-959.
17. Lichtenstein MP, Carriba P, Baltrons MA, Wojciak-Stothard B, Peterson JR, Garcia A, Galea E,. 2010. Secretase-independent and RhoGTPase/PAK/ERK-dependent regulation of cytoskeleton dynamics in astrocytes by NSAIDs and derivatives. J Alzheimers Dis 22: 1135-1155.
18. Manku MS, Horrobin DF,. 1976. Chloroquine, quinine, procaine, quinidine and clomipramine are prostaglandin agonists and antagonists. Prostaglandins 12: 789-801. (Pubitemid 8007550)
19. Niiro H, Otsuka T, Izuhara K, Yamaoka K, Ohshima K, Tanabe T, Hara S, Nemoto Y, Tanaka Y, Nakashima H, Niho Y,. 1997. Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils. Blood 89: 1621-1628. (Pubitemid 27097455)
20. O'Neill GP, Ford-Hutchinson AW,. 1993. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 330: 156-160. (Pubitemid 23265121)
21. Okamoto H, Cujec TP, Yamanaka H, Kamatani N,. 2008. Molecular aspects of rheumatoid arthritis: Role of transcription factors. FEBS J 275: 4463-4470.
22. Ono K, Han J,. 2000. The p38 signal transduction pathway: Activation and function. Cell Signal 12: 1-13. (Pubitemid 30017963)
23. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD,. 1999. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18: 7389-7394. (Pubitemid 30032121)
24. Pan MH, Lin-Shiau SY, Lin JK,. 2000. Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages. Biochem Pharmacol 60: 1665-1676.
25. Perkins ND,. 2007. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8: 49-62. (Pubitemid 46012014)
26. Scheuren N, Bang H, Munster T, Brune K, Pahl A,. 1998. Modulation of transcription factor NF-kappaB by enantiomers of the nonsteroidal drug ibuprofen. Br J Pharmacol 123: 645-652. (Pubitemid 128515013)
27. Shin JS, Park YM, Choi JH, Park HJ, Shin MC, Lee YS, Lee KT,. 2010. Sulfuretin isolated from heartwood of Rhus verniciflua inhibits LPS-induced inducible nitric oxide synthase, cyclooxygenase-2, and pro-inflammatory cytokines expression via the down-regulation of NF-kappaB in RAW 264.7 murine macrophage cells. Int Immunopharmacol 10: 943-950.
28. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB,. 2004. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 23: 9247-9258. (Pubitemid 40069695)
29. Tegeder I, Niederberger E, Israr E, Guhring H, Brune K, Euchenhofer C, Grosch S, Geisslinger G,. 2001a. Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen. FASEB J 15: 2-4.
30. Tegeder I, Pfeilschifter J, Geisslinger G,. 2001b. Cyclooxygenase- independent actions of cyclooxygenase inhibitors. FASEB J 15: 2057-2072. (Pubitemid 32927924)
31. Tsuji RF, Hoshino K, Noro Y, Tsuji NM, Kurokawa T, Masuda T, Akira S, Nowak B,. 2003. Suppression of allergic reaction by lambda-carrageenan: Toll-like receptor 4/MyD88-dependent and -independent modulation of immunity. Clin Exp Allergy 33: 249-258. (Pubitemid 36241384)
32. Vane JR,. 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231: 232-235.
33. Wahl C, Liptay S, Adler G, Schmid RM,. 1998. Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 101: 1163-1174. (Pubitemid 28125296)
34. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ,. 2001. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412: 346-351. (Pubitemid 32694385)
35. Weber C, Erl W, Pietsch A, Weber PC,. 1995. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation 91: 1914-1917.
36. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB,. 1999. Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 274: 27307-27314.
37. Yin MJ, Yamamoto Y, Gaynor RB,. 1998. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396: 77-80. (Pubitemid 28520452)